GLUE icon

Monte Rosa Therapeutics
GLUE

Overview Fund Activity

68 hedge funds and large institutions have $272M invested in Monte Rosa Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
68
Holders Change
-1
Holders Change %
-1.45%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
33
Reduced
10
Closed
10
Calls
$511K
Puts
–
Net Calls
+$511K
Net Calls Change
-$83K

Top Buyers

1
BBA
1
Baker Bros. Advisors
New York
$20.7M
2
ECM
2
ExodusPoint Capital Management
New York
$4.59M
3
BlackRock
3
BlackRock
New York
$26.4M
4
ACA
4
Avoro Capital Advisors
New York
$31.1M
5
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$26.7M

Top Sellers

1
CAM
1
Cormorant Asset Management
Massachusetts
$0
2
T. Rowe Price Investment Management
2
T. Rowe Price Investment Management
Maryland
$147K
3
Millennium Management
3
Millennium Management
New York
$0
4
TD Asset Management
4
TD Asset Management
Ontario, Canada
$799K
5
Squarepoint
5
Squarepoint
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Ameriprise
76
Ameriprise
Minnesota
– -$85.3K -10,955 Closed
Two Sigma Investments
77
Two Sigma Investments
New York
– -$78.7K -10,100 Closed
Nisa Investment Advisors
78
Nisa Investment Advisors
Missouri
– -$17K -2,190 Closed
1 2 3
4